Tag Archives: liver fibrosis

The PHCN’s News in Review Newsletter (13/03/17)

The PHCN's News in Review Newsletter (13/03/17)Welcome to the Pacific Hepatitis C Network (PHCN)‘s Hepatitis C News in Review Newsletter. This is where we review all of the major current issues and events around hepatitis C and hep C treatments. It is an email that includes links to our recent blog posts—including links to blog posts about the BC Ministry of Health announcing that they are now covering additional hepatitis C treatments.

PHCN’S STATEMENT ABOUT THE SUCCESSFUL NEGOTIATIONS FOR 3 NEW HEPATITIS C TREATMENTS

‘No One Left Behind!’

Pacific Hepatitis C Network (PHCN) is very happy to learn that effective March 21, an extensive list of hepatitis C treatments will be available through BC PharmaCare – at far better prices than they previously had been. The high cost of hepatitis C treatment has effectively restricted the numbers of people living with hepatitis C who could access treatment…

BC MINISTRY OF HEALTH COVERS ADDITIONAL HEPATITIS C TREATMENTS

Agreements between the pCPA and Gilead Sciences Canada, Merck Canada, and Bristol-Myers Squibb Canada were reached to provide several hepatitis C drugs at an improved cost:

  • Daklinza (daclatasvir) – new
  • Epclusa (sofosbuvir/velpatasvir) – new
  • Harvoni (ledipasvir/sofosbuvir)
  • Sovaldi (sofosbuvir)
  • Sunvepra (asunaprevir) – new
  • Zepatier (elbasvir/grazoprevir) – new

BC MINISTRY OF HEALTH ANNOUNCES END OF LIVER FIBROSIS F1> TREATMENT REQUIREMENT

PharmaCare announced that starting in 2018-19, they will provide coverage for any British Columbian living with chronic hepatitis C, regardless of the type or severity of their disease.

ONTARIO DRUG BENEFIT PROGRAM FUNDING HEPATITIS C DRUGS

Effective February 28, 2017, the following hepatitis C drug products will be funded under the Ontario Drug Benefit (ODB) Program for eligible ODB recipients for the treatment of hepatitis C.

• Harvoni (ledipasvir/sofosbuvir)
• Sovaldi (sofosbuvir)
• Epclusa (sofosbuvir/velpatasvir)
• Zepatier (elbasvir/grazoprevir)
• Daklinza (daclatasvir)
• Sunvepra (asunaprevir)
• Ibavyr (ribavirin)

CROI 2017

The Conference on Retroviruses and Opportunistic Infections (CROI), an annual preeminent HIV research meeting, was held in Seattle, Washington, February 13-16 this year. CROI gathers scientists researching epidemiology and biology of human retroviruses and associated diseases to discuss their findings. The following blog posts highlight HIV/HCV information that was at the conference.

REFLECTIONS BY PHCN’S PRESIDENT DARYL LUSTER

For more information about the topics in this newsletter, please click on the links, visit PHCN’s Hepatitis C Treatment Information Project, or email us.

Possible Softening of Liver Fibrosis Stage F1> Treatment Requirement

Possible Softening of Liver Fibrosis Stage F1> Treatment RequirementThe Pacific Hepatitis C Network has received reports that at least one Canadian assistance program offered by a pharmaceutical company is working with patients, on a case-by-case basis, to treat those with liver fibrosis stage F1. The status quo, requiring a liver fibrosis stage F2 or higher to access hep C treatment, in Canada may be changing and the Pacific Hepatitis C Network applauds this possible change.

If you have hepatitis C and are interested in treatment, please talk to your healthcare provider about it and keep regular tabs on your liver’s health.

Liver Fibrosis

Liver fibrosis is the early stage of liver scarring. It happens when a liver tries to heal itself and in the process creates scar tissue that can’t do the work of normal liver cells. Fibrosis doesn’t cause symptoms but can lead to portal hypertension or liver cirrhosis. A liver biopsy is used to diagnosis it. Fibrosis can be stopped and some of the changes reversed if the underlying condition is treated.

Liver Fibrosis Stages

There are five stages of liver fibrosis, stage 0 to stage 4 (stage F1-F4). Stage 0 means a liver is normal and doesn’t have fibrosis. Stage 4 is liver cirrhosis. Currently, BC PharmaCare requires a patient to have liver fibrosis stage 2 or higher in order to possibly qualify for hep C treatment coverage. At stage 2, one may still not know that their liver is damaged and may not experience liver failure symptoms such as yellow skin or eyes or abdominal pain.

More information about liver fibrosis and liver cirrhosis can be found in Understanding Cirrhosis of the Liver: First steps for the newly diagnosed, an easy-to-read resource that was put together by CATIE and the Canadian Association of Hepatology Nurses.